Key Considerations for Operationalizing CAR-THealthLeaders MediaThis is an excerpt from an article was originally published on the Revenue Cycle Advisor on September 13. Now that the Food and Drug Administration has approved chimeric antigen receptor … Continue reading
Stem Cell and Gene Therapy for ALSALS News TodayStem cell therapy is emerging as a potential approach for the treatment of ALS. There are many types of stem cells researchers use in their attempts to find an effective treatment for ALS. Induced pluripo… Continue reading
GeekWire |
Fred Hutch licenses new immunotherapy treatment to Mustang Bio, preps clinical trials in Seattle
GeekWire The technology is the basis for a new kind of CAR T immunotherapy treatment, which genetically engineers a patient’s immune cells to fight cancer. Similar treatments have been under development at biotech companies across the country for several years, … Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed ImmunotherapiesPharmiWeb.com (press release) |
GeekWire |
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
GlobeNewswire (press release) 14, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) … Fred Hutch licenses new immunotherapy treatment to Mustang Bio, preps pre-clinical trials in SeattleGeekWire |
|
$475000 for a Cancer Drug? Time to Put a Lid on Costs
Undark Magazine But much of the research that led to biologic drugs and treatments like CAR–T was funded by taxpayers. Novartis didn’t invent this half-million-dollar drug, and it’s questionable whether the Penn scientists from whom it bought a license invented it … OPINION: Don’t put profits over curing cancerKansas State Collegian |
|
$475000 for a Cancer Drug? Time to Put a Lid on Costs
Undark Magazine But much of the research that led to biologic drugs and treatments like CAR–T was funded by taxpayers. Novartis didn’t invent this half-million-dollar drug, and it’s questionable whether the Penn scientists from whom it bought a license invented it … OPINION: Don’t put profits over curing cancerKansas State Collegian |